226 related articles for article (PubMed ID: 19830388)
1. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
Wierzbicki R; Jonker DJ; Moore MJ; Berry SR; Loehrer PJ; Youssoufian H; Rowinsky EK
Invest New Drugs; 2011 Feb; 29(1):167-74. PubMed ID: 19830388
[TBL] [Abstract][Full Text] [Related]
2. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Saltz LB; Meropol NJ; Loehrer PJ; Needle MN; Kopit J; Mayer RJ
J Clin Oncol; 2004 Apr; 22(7):1201-8. PubMed ID: 14993230
[TBL] [Abstract][Full Text] [Related]
5. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
6. First-line single-agent cetuximab in patients with advanced colorectal cancer.
Pessino A; Artale S; Sciallero S; Guglielmi A; Fornarini G; Andreotti IC; Mammoliti S; Comandini D; Caprioni F; Bennicelli E; Andretta V; Siena S; Sobrero A
Ann Oncol; 2008 Apr; 19(4):711-6. PubMed ID: 18073221
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
11. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
12. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients.
Zlobec I; Molinari F; Martin V; Mazzucchelli L; Saletti P; Trezzi R; De Dosso S; Vlajnic T; Frattini M; Lugli A
World J Gastroenterol; 2010 Oct; 16(38):4823-31. PubMed ID: 20939111
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.
Muro K; Yoshino T; Doi T; Shirao K; Takiuchi H; Hamamoto Y; Watanabe H; Yang BB; Asahi D
Jpn J Clin Oncol; 2009 May; 39(5):321-6. PubMed ID: 19287023
[TBL] [Abstract][Full Text] [Related]
16. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.
Maréchal R; De Schutter J; Nagy N; Demetter P; Lemmers A; Devière J; Salmon I; Tejpar S; Van Laethem JL
BMC Cancer; 2010 Jun; 10():340. PubMed ID: 20591136
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience.
Pantelic A; Markovic M; Pavlovic M; Jancic S
J BUON; 2016; 21(1):70-9. PubMed ID: 27061533
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
[TBL] [Abstract][Full Text] [Related]
20. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
Frattini M; Saletti P; Romagnani E; Martin V; Molinari F; Ghisletta M; Camponovo A; Etienne LL; Cavalli F; Mazzucchelli L
Br J Cancer; 2007 Oct; 97(8):1139-45. PubMed ID: 17940504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]